Morningstar
•
Oct 29, 2026
Biogen Inc.: Biogen Earnings: Apellis Products Boost Growth Ahead of Key Lupus Readout
Summary
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Market Update: CB, F, FLEX, ISRG, TSCO, VZ
Oct 30, 2026
•
VZ, F, FLEX, TSCO, ISRG, CB
Analyst Report: Intuitive Surgical Inc
Oct 30, 2026
•
ISRG
Analyst Report: Eli Lilly & Co
Oct 30, 2026
•
LLY
Market Digest: AMZN, TT, KLAC, LLY, LMT, MSFT, PSA, TMO, MA, AGNC, HLT, STRL
Oct 30, 2026
•
TT, KLAC, MSFT, HLT, LMT, MA, AGNC, TMO, LLY, STRL, AMZN, PSA
Analyst Report: Bristol-Myers Squibb Company
Oct 30, 2026
•
BMY
